Nebulized Poractant alfa and nCPAP combo fails to reduce respiratory failure in preemies: Study
Nebulized Poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure (nCPAP) not effective in treating respiratory distress syndrome in premature babies, according to a new study published in the The Journal of Pediatrics
A study was conducted to investigate the efficacy and safety of nebulized Poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure (nCPAP) compared with nCPAP alone in premature babies with diagnosed RDS.
This randomized, controlled, multinational study was conducted in 28+0 to 32+6 weeks gestation infants. The primary outcome was the incidence of respiratory failure in the first 72 hours of life, defined as needing endotracheal surfactant and/or mechanical ventilation due to prespecified criteria. Secondary outcomes included the time to respiratory failure in the first 72 hours, duration of ventilation, mortality, incidence of bronchopulmonary dysplasia, and major associated neonatal comorbidities. In addition, the safety and tolerability of the treatments were assessed reporting the number and percentage of babies with treatment-emergent adverse events and adverse drug reactions during nebulization.
Results
129 babies were randomized. No significant differences were observed for the primary outcome: 24 (57%), 20 (49%) and 25 (58%) infants received endotracheal surfactant and/or mechanical ventilation within 72 hours in the Poractant alfa 200 mg/kg, Poractant alfa 400 mg/kg and nCPAP groups, respectively. Similarly, secondary respiratory outcomes did not differ among groups. Enrollment was halted early due to a change in the benefit-risk balance of the intervention. Nebulized Poractant alfa was well tolerated and safe, and no serious adverse events were related to the study treatment.
Thus, nebulized poractant alfa (at 200 and 400 mg/kg doses) delivered in combination with nasal continuous positive airway pressure did not reduce the likelihood of respiratory failure within the first 72 hours of life.
Reference:
A Randomized, Controlled Trial to Investigate the Efficacy of Nebulized Poractant Alfa in Premature Babies with Respiratory Distress Syndrome by Carlo Dani, et al. published in The Journal of Pediatrics.
https://www.jpeds.com/article/S0022-3476(22)00175-5/fulltext
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.